These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25635421)

  • 41. Clinical Characteristics, Radiological Features and Gene Mutation in 10 Chinese Families with Spinocerebellar Ataxias.
    Chen JW; Zhao L; Zhang F; Li L; Gu YH; Zhou JY; Zhang H; Meng M; Zhang KH; Le WD; Dong CB
    Chin Med J (Engl); 2015 Jul; 128(13):1714-23. PubMed ID: 26112709
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of Rivastigmine on Patients with Spinocerebellar Ataxia Type 3: A Case Series of Five Patients.
    Grobe-Einsler M; Vogt IR; Schaprian T; Hurlemann R; Klockgether T; Kaut O
    Neurodegener Dis; 2020; 20(2-3):104-109. PubMed ID: 32992315
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A neurological examination score for the assessment of spinocerebellar ataxia 3 (SCA3).
    Kieling C; Rieder CR; Silva AC; Saute JA; Cecchin CR; Monte TL; Jardim LB
    Eur J Neurol; 2008 Apr; 15(4):371-6. PubMed ID: 18312406
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical correlates of olfactory dysfunction in spinocerebellar ataxia type 3.
    Braga-Neto P; Felicio AC; Pedroso JL; Dutra LA; Bertolucci PH; Gabbai AA; Barsottini OG
    Parkinsonism Relat Disord; 2011 Jun; 17(5):353-6. PubMed ID: 21367642
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glucocerebrosidase gene variants in parkinsonian patients with Machado Joseph/spinocerebellar ataxia 3.
    Siebert M; Donis KC; Socal M; Rieder CR; Emmel VE; Vairo F; Michelin-Tirelli K; França M; D'Abreu AC; Bettencourt C; Lima M; Lopes Cendes I; Saraiva-Pereira ML; Jardim LB
    Parkinsonism Relat Disord; 2012 Feb; 18(2):185-90. PubMed ID: 22001711
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Progressive cognitive dysfunction in spinocerebellar ataxia type 3.
    Roeske S; Filla I; Heim S; Amunts K; Helmstaedter C; Wüllner U; Wagner M; Klockgether T; Minnerop M
    Mov Disord; 2013 Sep; 28(10):1435-8. PubMed ID: 23736996
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Recent advances in molecular genetics of spinocerebellar ataxia type 3/Machado-Joseph disease].
    Jia D; Jiang H; Tang B
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):660-2. PubMed ID: 19065526
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Carboxyl Terminus of Hsp70-Interacting Protein Is Increased in Serum and Cerebrospinal Fluid of Patients With Spinocerebellar Ataxia Type 3.
    Hu ZW; Yang ZH; Zhang S; Liu YT; Yang J; Wang YL; Mao CY; Zhang QM; Shi CH; Xu YM
    Front Neurol; 2019; 10():1094. PubMed ID: 31749756
    [No Abstract]   [Full Text] [Related]  

  • 50. Spin labeling artery method perfusion MRI study of SPG4 and SCA3/MJD.
    Xing W; Wang XY; Liao XX; Liao WH; Shen L
    Magn Reson Imaging; 2014 Dec; 32(10):1330-4. PubMed ID: 25172988
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factors influencing disease progression in autosomal dominant cerebellar ataxia and spastic paraplegia.
    Tezenas du Montcel S; Charles P; Goizet C; Marelli C; Ribai P; Vincitorio C; Anheim M; Guyant-Maréchal L; Le Bayon A; Vandenberghe N; Tchikviladzé M; Devos D; Le Ber I; N'Guyen K; Cazeneuve C; Tallaksen C; Brice A; Durr A
    Arch Neurol; 2012 Apr; 69(4):500-8. PubMed ID: 22491195
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MicroRNA profiling in the serums of SCA3/MJD patients.
    Shi Y; Huang F; Tang B; Li J; Wang J; Shen L; Xia K; Jiang H
    Int J Neurosci; 2014 Feb; 124(2):97-101. PubMed ID: 23879331
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular genetics of hereditary spinocerebellar ataxia: mutation analysis of spinocerebellar ataxia genes and CAG/CTG repeat expansion detection in 225 Italian families.
    Brusco A; Gellera C; Cagnoli C; Saluto A; Castucci A; Michielotto C; Fetoni V; Mariotti C; Migone N; Di Donato S; Taroni F
    Arch Neurol; 2004 May; 61(5):727-33. PubMed ID: 15148151
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Reliability of the Japanese version of the Scale for the Assessment and Rating of Ataxia (SARA)].
    Sato K; Yabe I; Soma H; Yasui K; Ito M; Shimohata T; Onodera O; Nakashima K; Sobue G; Nishizawa M; Sasaki H
    Brain Nerve; 2009 May; 61(5):591-5. PubMed ID: 19514520
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Machado-Joseph disease/SCA3 and myotonic dystrophy type 1 in a single patient.
    Miura S; Ohyagi Y; Miike T; Noda K; Motomura K; Ayabe M; Aizawa H; Taniwaki T
    Clin Neurol Neurosurg; 2009 Dec; 111(10):791-4. PubMed ID: 19713033
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [CAG trinucleotide mutation detection in patients with hereditary spinocerebellar ataxia].
    Tang B; Xia J; Wang D; Tang X; Shen L; Liu C; Dai H; Yan X; Pan Q; Xiao J; Zhang B; Ou Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 1999 Oct; 16(5):281-4. PubMed ID: 10514531
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Botulinum toxin type A for treatment of spasticity in spinocerebellar ataxia type 3 (Machado-Joseph disease).
    Freeman W; Wszolek Z
    Mov Disord; 2005 May; 20(5):644. PubMed ID: 15747361
    [No Abstract]   [Full Text] [Related]  

  • 58. [Clinico-genetic study of type I spinocerebelllar ataxia].
    Svetel M; Culjković B; Sternić N; Dragasević B; Stojković I; Romac S; Kostić VS
    Srp Arh Celok Lek; 1999; 127(5-6):157-62. PubMed ID: 10500422
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of speech therapy on quality of life in patients with spinocerebelar ataxia type 3.
    Diaféria G; Bommarito S; Braga Neto P; Park SW; Padovani M; Haddad F; Haddad L; Voos MC; Chien HF; Pedroso JL; Barsottini O
    Arq Neuropsiquiatr; 2022 Oct; 80(10):1017-1025. PubMed ID: 36535286
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Content Validity of the Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) Instrument in Spinocerebellar Ataxia.
    Potashman M; Rudell K; Pavisic I; Suminski N; Doma R; Heinrich M; Abetz-Webb L; Beiner MW; Kuo SH; Rosenthal LS; Zesiwicz T; Fife TD; van de Warrenburg BP; Ristori G; Synofzik M; Perlman S; Schmahmann JD; L'Italien G
    Cerebellum; 2024 May; ():. PubMed ID: 38713312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.